Aducanumab

Drug / MedicationMentioned in 1 video

A monoclonal antibody against amyloid developed by Biogen, which underwent two parallel Phase 3 trials (EMERGE and ENGAGE) with mixed results but ultimately showed promise in high-dose groups. Its FDA approval decision is highly anticipated.

Videos Mentioning Aducanumab

164 - Diagnosing, preventing, & treating Alzheimer’s disease, & life lessons from dementia patients

164 - Diagnosing, preventing, & treating Alzheimer’s disease, & life lessons from dementia patients

Peter Attia MD

A monoclonal antibody against amyloid developed by Biogen, which underwent two parallel Phase 3 trials (EMERGE and ENGAGE) with mixed results but ultimately showed promise in high-dose groups. Its FDA approval decision is highly anticipated.